about
Cytomegalovirus and ulcerative colitis: Place of antiviral therapyReview article: biosimilars are the next generation of drugs for liver and gastrointestinal diseasesMultidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitis.[An uncommon use of argon plasma coagulation: endoscopic transection of self-expanding metallic stents].Fetal death in utero and miscarriage in a patient with Crohn's disease under therapy with ustekinumab: case-report and review of the literature.Golimumab for the treatment of ulcerative colitis.Health care-associated hepatitis C virus infection.Dectin-1 is essential for reverse transcytosis of glycosylated SIgA-antigen complexes by intestinal M cellsPrevention and treatment of postoperative Crohn's disease recurrence with anti-TNF therapy: a meta-analysis of controlled trials.Comparison of adiponectin concentration between pancreatic cancer and colorectal cancerGolimumab pharmacokinetics in ulcerative colitis: a literature reviewThe level of epidermal growth factor receptors expression is correlated with the advancement of colorectal adenoma: validation of a surface biomarker.Thiopurine metabolism monitoring: implications in inflammatory bowel diseases.Management of cytomegalovirus infection in inflammatory bowel diseases.Quantification of cytomegalovirus viral load.Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis.Tacrolimus induction followed by maintenance monotherapy is useful in selected patients with moderate-to-severe ulcerative colitis refractory to prior treatment.Pharmacokinetics in IBD: ready for prime time?Systematic review: new serological markers (anti-glycan, anti-GP2, anti-GM-CSF Ab) in the prediction of IBD patient outcomes.The Genotyping Resistance Profile of the Pol Gene Detected in Blood of Newly Diagnosed HIV-Positive Men Is Durably Archived in the Gut Whatever the Time of Initiation of cART.Pharmacokinetics of Infliximab and Reduction of Treatment for Inflammatory Bowel Diseases.Advances in the Development of Janus Kinase Inhibitors in Inflammatory Bowel Disease: Future Prospects.Combination of corticosteroids and 5-aminosalicylates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: A global survey of physicians' practice.Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease.Difficult endoscopic diagnosis of a pancreatic plasmacytoma: Case report and review of literature.Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab.Laparoscopy could be the best approach to treat colorectal cancer in selected patients aged over 80 years: Outcomes from a multicenter study.Adherence to infliximab therapy in inflammatory bowel disease patients in a real-life setting.Impact of Infliximab and Cyclosporine on the Risk of Colectomy in Hospitalized Patients with Ulcerative Colitis Complicated by Cytomegalovirus-A Multicenter Retrospective Study.Response to Zidar and Tepes.Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents.Major influence of CD4 count at the initiation of cART on viral and immunological reservoir constitution in HIV-1 infected patients.[Neuromeningeal cryptococcosis and alcoholic cirrhosis]Brief Report: A High Rate of β7+ Gut-Homing Lymphocytes in HIV-Infected Immunological Nonresponders is Associated With Poor CD4 T-Cell Recovery During Suppressive HAART[Targeting and role of α4β7 integrin in the pathophysiology of IBD and HIV infection].Infliximab Does Not Worsen Outcomes During Flare-ups Associated with Cytomegalovirus Infection in Patients with Ulcerative Colitis.The impact of cytomegalovirus reactivation and its treatment on the course of inflammatory bowel disease.Trend towards dose reduction of azathioprine as monotherapy in inflammatory bowel disease patients: what about for combination therapy?Association between 6-thioguanine nucleotides levels and clinical remission in inflammatory disease: a meta-analysis.Local appendiceal dysbiosis: the missing link between the appendix and ulcerative colitis?
P50
Q26766101-891AD95F-44E1-4D66-BD76-FFDDA8B52172Q27013577-563D8F29-53D4-41BE-8A0D-04D543C5BA1AQ33268368-F47FFFF4-DDFF-4E76-B4EE-CD2D0754A3B0Q33326918-BDB8EAFA-B862-4842-95C2-1540387F8AC0Q33815262-BEE16412-E0B9-49A7-A309-021343D9B978Q33852257-2570158A-DF14-4BEE-B756-705297AF376CQ34696503-AB22B401-C586-4F92-AFA7-A50A2B91AA19Q34998132-4BE84F80-4609-4733-AEAC-35A2DA586271Q35501623-5C6D6D2C-7CE5-4C1D-B1CE-B8D8569137A6Q36097245-88E1A3AF-2200-4253-8872-D36A80662E2FQ37671983-7F09828E-A27E-4FC2-9A85-FADE15EE267DQ37725469-F9D30A22-2AB1-40D3-843A-9DBD9ABFC3A1Q37772541-A0C003EB-655E-4B6B-87E3-46C5520BB814Q38005883-968919C5-C36C-495A-8030-935877783FEEQ38171537-6323D987-75A2-4A40-BE97-8DF725531C57Q38211991-5A54F53B-9A9E-48BA-82D9-37E922A42BEBQ38229318-33CD9B8C-1454-4736-88E5-D9102A93D273Q38244883-EE3EF67A-67BF-493F-B8FF-72076CC7C31BQ38280973-BF94B2B3-AAA2-4F85-AC88-57592F67FEC1Q38375046-BF397EFC-3814-48F8-8E82-15C8CE3D1E74Q38669977-C71E1A9C-3EED-4138-B369-3AB1BFEBCD2FQ38681918-2AAFD885-622F-458B-BD88-A733DD6D93D1Q38775880-549C306E-B4E9-4E6C-AD44-4EAF2A49A7DFQ39077823-59A735D5-C28E-41FC-A19F-7130260375B6Q39155433-6889438E-5944-472A-96D9-475DD7A927B1Q39175362-F517B270-719A-473E-88D5-C0C1FFE11882Q39302839-01F78F3F-79EF-491F-AC4C-0E3DEBAF170FQ40072786-F56614E2-B42A-4A6A-8E51-31AFFE98A402Q40181878-C42299B4-804A-462B-A4B4-417751F34FD0Q40304336-1895BE6E-4694-4E11-9348-CD643220029BQ40472089-0336B08C-4F7D-4E51-8163-6DB3E52D0469Q40630115-06F0C7EC-80C5-41FA-8F85-B7703F80FF85Q40658875-1CC75634-B307-4621-A078-E5FEBBA303D4Q40699445-5B509BC0-9D97-4FAE-9FA4-8396F098784DQ40946143-2F9F0BE2-EC2F-42EE-987A-8A79B230083DQ41266366-4584D22C-FCE7-4807-B911-E347BE638B90Q42238383-A65D2E4F-9845-4BDC-BD36-BB6866A6742CQ42319267-6254524A-5393-4BDD-93F2-4FC1C4D1EEA6Q42707435-EDBAEFD6-0BBE-4CAF-8FED-C24FFF3526A1Q43423479-078C6D15-D97F-4E66-8F8C-60E937C28CAC
P50
description
researcher
@en
name
X Roblin
@en
X Roblin
@nl
type
label
X Roblin
@en
X Roblin
@nl
prefLabel
X Roblin
@en
X Roblin
@nl
P106
P31
P496
0000-0002-7929-4878